CoChat

A Randomized, Controlled Trial of Gabapentin Enacarbil in Subjects with Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

Rauck, Richard, Makumi, Clare W., Schwartz, Sherwyn, Graff, Ole, Meno‐Tetang, Guy, Bell, Christopher F., Kavanagh, Sarah T., McClung, Carrie L. · 2013 · Pain Practice
Cited by 61

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Background: Gabapentin enacarbil (GE n), a transported prodrug of gabapentin, provides sustained, dose‐proportional gabapentin exposure. The purpose of this study was to investigate the dose response of GE n to select the optimal dose(s) for clinical use in subsequent diabetic peripheral neuropathy (DPN) trials. Methods: This was a multicenter, randomized, double‐blind, double‐dummy, parallel group, placebo‐controlled trial with a study duration of approximately 20 weeks (Clinicaltrials.gov database, Identifier ! NCT 00643760). Pregabalin (PGB) (Lyrica®; Pfizer Inc.) was used as an active control to provide assay sensitivity of the trial. A total of 421 adult subjects with DPN were randomized in a ratio of 2:1:1:1:2 to receive oral GE n 3,600 mg/day, GE n 2,400 mg/day, GE n 1,200 mg/day, PGB 300 mg/day, or matching placebo, respectively. The primary efficacy endpoint was change from baseline to end of maintenance treatment with respect to the mean 24‐hour average pain intensity score based on an 11‐point Pain Intensity Numerical Rating Scale (PI‐NRS). Safety and tolerability assessments included treatment‐emergent adverse events (TEAE s), laboratory evaluations, vital signs, electrocardiograms (ECG), neurological examination, and pedal edema. Results: The adjusted mean difference vs. placebo at the end of maintenance treatment with respect to the mean 24‐hour average PI‐NRS pain intensity score for GE n 1,200 mg (−0.35; [95% CI: −1.02, 0.31]; P = 0.295), GE n 2,400 mg (−0.02; [95% CI: −0.71, 0.66]; P = 0.946), and GE n 3,600 mg (−0.55; [95% CI: −1.10, 0.01]; P = 0.105) was not statistically significant. The active control, PGB (300 mg/day), did not differentiate from placebo. Conclusion: Overall, none of the GE n treatment groups differentiated from placebo. Analyses of the secondary endpoints showed comparable results across treatment groups. However, the majority of the endpoints, including all of the pain endpoints, showed the largest numerical treatment difference was between GE n 3,600 mg and placebo. The active control, PGB (300 mg/day), did not differentiate from placebo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/papr.12014

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

Metadata

Authors
Rauck, R., Makumi, C. W., Schwartz, S., Graff, O., Meno‐Tetang, G., Bell, C. F., Kavanagh, S. T., & McClung, C. L.
Venue
Pain Practice
Publisher
Wiley
Published
2012-11-27
Volume
13
Issue
6
Pages
485-496
ISSN
  • 1530-7085 (ISSN-L)
  • 1533-2500
OpenAlex
W2085427610
Cited by
61
References
2
FWCI
1.89
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.